Download PDF
CC BY-NC-ND 4.0 · South Asian J Cancer 2017; 06(02): 089-090
DOI: 10.4103/2278-330X.208855
Letters to the Editor

Complete response with crizotinib in two children with chemotherapy resistant neuroblastoma

Priyanka Verma
Department of Pediatric Oncology and Hematology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India
,
Sandeep Jain
Department of Pediatric Oncology and Hematology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India
,
Gauri Kapoor
Department of Pediatric Oncology and Hematology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India
› Author Affiliations
Source of Support: Nill.
› Further Information
Also available at
 PDF Download Permissions and Reprints


Publication History

Article published online:
22 December 2020

© 2017. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. https://creativecommons.org/licenses/by-nc-nd/4.0/.

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Balwierz W, Wieczorek A, Klekawka T, Garus K, Bolek-Marzec K, Perek D, et al. Treatment results of children with neuroblastoma: Report of Polish Pediatric Solid Tumor Group. Przegl Lek 2010;67:387-92.
  • 2 Carpenter EL, Mossé YP. Targeting ALK in neuroblastoma – Preclinical and clinical advancements. Nat Rev Clin Oncol 2012;9:391-9.
  • 3 Mossé YP, Lim MS, Voss SD, Wilner K, Ruffner K, Laliberte J, et al. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: A Children's Oncology Group phase 1 consortium study. Lancet Oncol 2013;14:472-80.
  • 4 Yan B, Kuick CH, Lim M, Venkataraman K, Tennakoon C, Loh E, et al. Platform comparison for evaluation of ALK protein immunohistochemical expression, genomic copy number and hotspot mutation status in neuroblastomas. PLoS One 2014;9:e106575.